Alteplase
Generic Name: alteplase
Brand Names:
Cathflo Activase
DESCRIPTION Cathflo ® Activase ® (Alteplase) is a tissue plasminogen activator (t‑PA) produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissue‑type plasminogen activator (t‑PA) obtained from an established human cell line.
Overview
DESCRIPTION Cathflo ® Activase ® (Alteplase) is a tissue plasminogen activator (t‑PA) produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissue‑type plasminogen activator (t‑PA) obtained from an established human cell line.
Uses
INDICATIONS AND USAGE Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.
Dosage
DOSAGE AND ADMINISTRATION Cathflo ® Activase ® (Alteplase) is for instillation into the dysfunctional catheter at a concentration of 1 mg/mL. • Patients weighing ≥30 kg: 2 mg in 2 mL • Patients weighing <30 kg: 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL If catheter function is not restored at 120 minutes after 1 dose of Cathflo Activase, a second dose may be instilled (see Instructions for Administration ). There is no efficacy or safety information on dosing in excess of 2 mg per dose for this indication. Studies have not been performed with administration of total doses greater than 4 mg (two 2‑mg doses).
Side Effects
ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in Section PRECAUTIONS of the label: Bleeding Hypersensitivity In the clinical trials, the most serious adverse events reported after treatment were sepsis (see PRECAUTIONS, Infections ), gastrointestinal bleeding, and venous thrombosis. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Trials 1 and 2 The data described for Trials 1 and 2 reflect exposure to Cathflo Activase in 1122 patients, of whom 880 received a single dose and 242 received two sequential doses of Cathflo Activase.
Interactions
Drug Interactions The interaction of Cathflo Activase with other drugs has not been formally studied. Concomitant use of drugs affecting coagulation and/or platelet function has not been studied.
Warnings
WARNINGS None. CONTRAINDICATIONS Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see DESCRIPTION ).
Pregnancy
Pregnancy Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at a dose (3 mg/kg) approximately 50 times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at a dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs. There are no adequate and well‑controlled studies in pregnant women.
Storage
HOW SUPPLIED Cathflo Activase (Alteplase) for injection is supplied as a sterile, lyophilized powder in 2 mg vials. Cathflo ® Activase ® is available in a carton that contains one 2 mg vial of Cathflo ® Activase ® (Alteplase): NDC 50242‑041‑64 or a carton that contains ten 2 mg vials of Cathflo ® Activase ® (Alteplase): NDC 50242-041-10.
Frequently Asked Questions
What is Alteplase used for?▼
INDICATIONS AND USAGE Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.
What are the side effects of Alteplase?▼
ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in Section PRECAUTIONS of the label: Bleeding Hypersensitivity In the clinical trials, the most serious adverse events reported after treatment were sepsis (see PRECAUTIONS, Infections ), gastrointestinal bleeding, and venous thrombosis. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Trials 1 and 2 The data described for Trials 1 and 2 reflect exposure to Cathflo Activase in 1122 patients, of whom 880 received a single dose and 242 received two sequential doses of Cathflo Activase.
Can I take Alteplase during pregnancy?▼
Pregnancy Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at a dose (3 mg/kg) approximately 50 times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at a dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs. There are no adequate and well‑controlled studies in pregnant women.
What are the important warnings for Alteplase?▼
WARNINGS None. CONTRAINDICATIONS Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see DESCRIPTION ).
Related Medications
Aconitum Napellus, Aralia Quinquefolia, Chininum Arsenicosum, Coffea Cruda, Colchicum Autumnale, Crataegus Oxyacantha Fruit, Echinacea Purpurea, Eschscholtzia Californica, Humulus Lupulus, Ignatia Amara, Lycopus Virginicus, Nux Vomica, Passiflora Incarnata, Scutellaria Lateriflora, Strychninum Phosphoricum, Thyroidinum, Viscum Album Fruiting Top, Yellow Jasmine Root
aconitum napellus, aralia quinquefolia, chininum arsenicosum, coffea cruda, colchicum autumnale, crataegus oxyacantha fruit, echinacea purpurea, eschscholtzia californica, humulus lupulus, ignatia amara, lycopus virginicus, nux vomica, passiflora incarnata, scutellaria lateriflora, strychninum phosphoricum, thyroidinum, viscum album fruiting top, yellow jasmine root
Non-Standardized Food Allergenic Extract [EPC]
Uses: For temporary relief of minor: occasional sleeplessness* menstrual cramping* restlessness* irritability* *Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Ascorbicum Acidum, Cysteinum, Manganese Gluconate, Alpha-ketoglutaricum Acidum, Fumaricum Acidum, Germanium Sesquioxide, Iodium, Magnesium Metallicum, Natrum Oxalaceticum, Pulsatilla (pratensis), Thyroidinum (suis), Vanadium Metallicum
ascorbicum acidum, cysteinum, manganese gluconate, alpha-ketoglutaricum acidum, fumaricum acidum, germanium sesquioxide, iodium, magnesium metallicum, natrum oxalaceticum, pulsatilla (pratensis), thyroidinum (suis), vanadium metallicum
Vitamin C [EPC]
HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to headache, joint pain, sweating, congestion, and fatigue.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.
Diphenylcyclopropenone
diphenylcyclopropenone
Dosage form: POWDER. Active ingredients: DIPHENCYPRONE (1 g/g). Category: BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.